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Abstract 
Background: Craniomaxillofacial defects secondary to trauma, tumor resection, or congenital malformations are 
frequent unmet challenges, due to suboptimal alloplastic options and limited autologous tissues such as bone. Sig-
nificant advances have been made in the application of adipose-derived stem/stromal cells (ASCs) in the pre-clinical 
and clinical settings as a cell source for tissue engineering approaches. To fully realize the translational potential of 
ASCs, the identification of optimal donors for ASCs will ensure the successful implementation of these cells for tissue 
engineering approaches. In the current study, the impact of obesity on the osteogenic differentiation of ASCs was 
investigated.
Methods: ASCs isolated from lean donors (body mass index <25; lnASCs) and obese donors (body mass index >30; 
obASCs) were induced with osteogenic differentiation medium as monolayers in an estrogen-depleted culture sys-
tem and on three-dimensional scaffolds. Critical size calvarial defects were generated in male nude mice and treated 
with scaffolds implanted with lnASCs or obASCs.
Results: lnASCs demonstrated enhanced osteogenic differentiation in monolayer culture system, on three-dimen-
sional scaffolds, and for the treatment of calvarial defects, whereas obASCs were unable to induce similar levels of 
osteogenic differentiation in vitro and in vivo. Gene expression analysis of lnASCs and obASCs during osteogenic dif-
ferentiation demonstrated higher levels of osteogenic genes in lnASCs compared to obASCs.
Conclusion: Collectively, these results indicate that obesity reduces the osteogenic differentiation capacity of ASCs 
such that they may have a limited suitability as a cell source for tissue engineering.
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Background
Bone defects in the craniomaxillofacial skeleton can 
occur as a result of congenital defects or acquired inju-
ries secondary to trauma, surgery, infection, and cancer. 
Current options for treatment include autologous bone 
grafts and microvascular free flaps. However, drawbacks 
of these procedures include limited donor tissue, donor 
site morbidity, unpredictable resorption rate, and high 
infection rates of both the donor and recipient sites [1–
4]. Furthermore, in the osteoporotic patient, these bone 
grafts are likely to be osteoporotic as well, limiting their 
ability to heal fracture sites. Additionally, alloplastic 
materials, though temporizing, often are complicated by 
breakdown, resorption, or infection. Therefore, recon-
struction of these bone defects remains a significant chal-
lenge with high morbidity.
Alternative strategies have recently utilized tissue-
engineering approaches to supplement biodegradable 
scaffolds with adipose-derived stromal/stem cells (ASCs) 
and shown significant promise in treating craniomaxil-
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stromal cells with the capacity to differentiate into osteo-
blasts [5–7]. ASCs secrete an abundance of growth fac-
tors that assist in angiogenesis and bone regeneration 
[8, 9]. Animal experiments have shown the feasibility of 
healing critical size calvarial and mandibular defects with 
ASC seeded scaffolds [10–13]. Similar efficacy has been 
demonstrated with ASC seeded scaffolds for the treat-
ment of femoral defects and vertebral defects [14, 15]. 
Human clinical trials have demonstrated the regenerative 
potential of ASC seeded scaffolds to aid in craniomaxil-
lofacial hard tissue reconstruction [16, 17]. Implantation 
of restorable scaffold material seeded with ASCs demon-
strated successful integration of the constructs with the 
surrounding skeleton [16, 17]. The bony defects demon-
strated significant remodeling that likely contributed to 
the long-term engraftment of the constructs and regen-
eration of the tissue.
With the growing interest and promise of novel tis-
sue engineering approaches utilizing ASCs as the cell 
source, identifying the optimal donor and factors that 
may alter ASC biology is pertinent to the success of this 
method. Alterations to ASC biology may dramatically 
reduce the attachment of the ASCs to the scaffold and 
reduce the efficacy of the construct for bone healing. 
Recently, studies have shown that ASCs isolated from 
older donors displayed reduced viability, self-renewal 
capacity, proliferation, and differentiation potential, 
compared to ASCs isolated from young donors [18, 19]. 
The effects of aging on ASC osteogenesis translated to 
reduced formation of osteoblast-like cells on scaffolds 
[19]. ASCs have also been shown to promote the sur-
vival of endothelial cells and coordinate with the local 
environment to form vascular networks to assist in 
healing [20–22]. However, the angiogenic effects of 
ASCs are compromised with advanced age and follow-
ing continuous exposure to chronic diseases, such as 
coronary artery disease [23–25]. Together, these stud-
ies demonstrate that exposure to chronic inflammation 
may impact stem cell function, and these alterations 
may be detrimental for the success of tissue engineering 
approaches.
Obesity is associated with low-grade chronic inflam-
mation and is characterized by excess lipid accumulation 
and overproduction of inflammatory cytokines associ-
ated with the adipocyte hyperplasia and hypertrophy 
[26, 27]. Studies have shown that ASCs isolated from 
obese donor have loss of stemness markers and increased 
expression of inflammatory cytokines [28]. Furthermore, 
the recipient site of ASC implantation in diabetic patients 
is often compromised with regards to its angiogenic and 
osteogenic niche. Additional studies have postulated that 
the reason ASCs isolated from obese donors have altered 
biological properties is due to their close proximity to 
the inflammatory microenvironment [29, 30]. Neverthe-
less, it remains to be determined whether obesity influ-
ences the osteogenic differentiation potential ASCs on 
biodegradable scaffolds and whether these effects would 
impede translational applications of ASCs for bone 
regeneration.
Human ASCs isolated from lean and obese donors 
were characterized based on osteogenic differentiation 
in adherent cultures and on scaffolds. Critical size cal-
varial defects were generated in nude mice and treated 
with scaffolds seeded with ASC isolated from lean or 
obese donors. Both in vitro and in vivo analysis demon-
strated the reduced osteogenic differentiation of ASCs 
from obese donors, which corresponded to changes in 
the gene expression profile. Collectively, these findings 
indicate that obesity significant reduces the osteogenic 
capacity of ASCs and that ASCs isolated from obese 




Primary human ASCs were obtained from subcutaneous 
abdominal adipose tissue of 12 Caucasian females under-
going elective liposuction. Tissues were obtained with 
written informed consent under a protocol reviewed and 
approved by the Pennington Biomedical (Baton Rouge, 
LA) Institutional Review Board. Lipoaspirates were pro-
cessed as previously described [31]. The mean BMI for 
the ASCs isolated from donors with a BMI between 20 
and 24.9 (lnASCs) was 22.7 ± 1.9 (N = 6 donors), while 
the mean BMI for the ASCs isolated from donors with 
a BMI greater than 30 (obASCs) was 32.7 ± 3.7 (N = 6 
donors). The mean age of the subjects for each group of 
donors was as follows: lnASCs (38.8 ± 7.0) and obASCs 
(42.5  ±  8.9). No statistical significance in age was 
observed between the donor groups. Cells were charac-
terized as previously described by our group [30–33].
Cell culture
Frozen vials of approximately 106 ASCs were thawed, 
plated onto 150 cm2 culture dishes (Nunc, Rochester, NY) 
in 20 ml CCM and incubated at 37 °C with 5 % humidi-
fied CO2. After 24  h, medium was removed and adher-
ent, viable cells were washed with PBS, harvested with 
0.25 % trypsin/1 mM EDTA (Gibco; Grand Island, NY), 
and expanded in CCM, which consisted of α-Minimal 
Essential Medium (Gibco), 20 % fetal bovine serum (FBS; 
Atlanta Biologicals, Lawrenceville, GA), 100 units per 
ml penicillin/100 µg/mL streptomycin (P/S; Gibco), and 
2 mM l-glutamine (Gibco). Medium was replaced every 
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3–4 days. For all experiments, cells between passages 2–6 
were used.
Osteogenic differentiation of monolayer cultures
ASCs were cultured in six-well plates in CCM until 70 % 
confluence. Medium was replaced with fresh osteogenic 
differentiation medium (ODM) consisting of CCM sup-
plemented with 50  μM ascorbate 2-phosphate (Sigma, 
St. Louis, MO), 10  mM β-glycerol phosphate (Sigma), 
and 10  nM dexamethasone (Sigma). Where indicated, 
the FBS in ODM was substituted for charcoal dextran 
stripped fetal bovine serum (CDS-ODM; Atlanta Bio-
logicals) and supplemented with log fold increases of 
17β-estradiol (E2) from 100  pM to 10  μM of estradiol. 
After 14 or 21 days, cells undergoing osteogenic differ-
entiation in ODM or CDS-ODM were fixed in 10 % for-
malin for 1  h, washed with distilled water, and stained 
with 1 % Alizarin Red (pH 4.1) to visualize calcium dep-
osition in the extracellular matrix as a marker of early 
osteogenesis. Images were acquired at 4  ×  magnifica-
tion on Eclipse TE200 (Nikon; Melville, NY) with a digi-
tal camera (Nikon DXM1200F) using ACT-1 software 
(Nikon). For quantification, Alizarin Red was extracted 
from each well with 10  % cetylpyridinium chloride 
(CPC) and read at 584 nm (FLUOstar optima). To nor-
malize to the amount of protein in each sample, protein 
extraction with RIPA buffer (Pierce, Thermo Scientific) 
and protein quantification with the BCA assay (Thermo 
Scientific) was performed according to manufacturer’s 
instructions.
PLGA scaffold preparation
PLGA scaffolds were fabricated from 85/15 PLGA by 
solvent casting and lyophilization process, as previ-
ously described [34]. The mixture was poured into 
a polydimethylsiloxane mold (Dow Corning; Mid-
land, MI) to generate 4  mm diameter scaffolds and 
immediately transferred to a −20  °C freezer. Once 
the mixture solidified, the scaffolds were immediately 
freeze-dried for 4 h and sterilized in 70 % ethanol prior 
to experimentation.
Cell seeding on PLGA scaffolds
Scaffolds were soaked in PBS for 1 h prior to cell seed-
ing to remove residual ethanol during the sterilization 
process. Equal number of ASCs from all ASC donors 
(N  =  6) were pooled and directly loaded onto a sin-
gle face of each scaffold at a concentration of 6000 
cells per μl for a total volume of 25 μl for 30 min. The 
scaffolds were subsequently submerged in 100  μl of 
growth medium overnight at 37  °C with 5  % humidi-
fied CO2.
Osteogenic differentiation of ASCs seeded on PLGA 
scaffolds
To assess osteogenic differentiation of ASCs seeded on 
PLGA scaffolds, scaffolds were cultured for 7  days in 
CDS-CCM or CDS-ODM. Where indicated, medium 
was supplemented with vehicle, log fold increases of 
17β-estradiol from 100 pM to 10 μM. After 7 days, scaf-
folds were rinsed with PBS, fixed in 70  % ethanol, and 
stained with 40  mM Alizarin Red (pH 4.1) to visual-
ize calcium deposition. For quantification, Alizarin Red 
was eluted from each scaffold with 10 % CPC and opti-
cal density was read at 584 nm (FLUOstar optima; BMG 
Labtech, Cary, NC).
Critical size calvarial defect model
All procedures involving animals were conducted in 
compliance with State and Federal laws, standards of 
the US Department of Health and Human Services, and 
guidelines established by Tulane University Institutional 
Animal Care and Use Committee (IACUC). All proto-
cols were reviewed and approved by the IACUC prior 
to implementation. Male Crl:NU-Foxn1nu CD-1 nude 
mice (60  days old) were obtained from Harlan Labora-
tories (Indianapolis, IN). After anesthesia, the surgical 
site was cleaned with povidone/iodine solution (Thermo 
Scientific) and an incision was made just off the sagittal 
midline. Periosteum over the region of the incision was 
incised and lateralized. A unilaterial 4 mm full thickness 
critical size calvarial defect was created using diamond-
coated trephine bits in the nonsuture associated portion 
of the right parietal bone, taking extreme care to avoid 
dural injury.
Mice were divided into four treatment groups (N = 6 
per group): no scaffold (empty); scaffold alone, lnASC-
seeded scaffold, or obASC-seeded scaffold. Following 
implantation, the skin was sutured and animals were 
monitored post-operatively. After 16  weeks, animals 
(N = 3 per time point) were euthanized by cervical dislo-
cation after exposure to CO2. Organs were removed and 
fixed in 10 % formalin for additional analyses.
Micro‑computed tomography (microCT)
Following fixation, the dorsal half of the cranium was 
scanned (Scanco model 40; Scanco Medical AG, Basser-
dorf, Switzerland) in a dorsal plane in fluid (70 % ETOH) 
at 55 kV, 0.3-s integration time, with a 15 µm voxel size 
and 15  µm slice thickness. The region of interest was 
defined as a 4  mm-diameter core including the defect. 
Bone regeneration was determined by bone volume rela-
tive to total volume for each group and normalized to the 
calvarial defects that were left untreated using standard 
nomenclature [35].
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Histological analysis
Formalin fixed calvaria were decalcified in 10  % EDTA 
(Sigma), paraffin embedded, and sectioned. Tissue sec-
tions stained with hematoxylin and eosin (Richard-
Allan Scientific, Thermo Scientific; Waltham, MA), 
Aniline Blue (Sigma), or Tartrate-Resistant Acid Phos-
phate (TRAP; Sigma). After staining, slides were dehy-
drated in graded solutions of ethanol and Sub-X in the 
final step, and sealed with Permount Mounting Medium 
(Sigma). Images were acquired and quantified with the 
ScanScope CS2 (Aperio, Vista, CA) running Image Scope 
(Aperio).
RNA isolation, cDNA synthesis, quantitative RT‑PCR
ASCs cultured in CDS-ODM for 1, 7, 14 and 21  days 
were collected, and total cellular RNA was extracted 
from ASCs using the RNeasy Mini Kit (Qiagen, Valen-
cia, CA), purified with DNase I digestion (Invitrogen) 
according to manufacturer’s instructions, and reverse 
transcribed using the SuperScript VILO cDNA syn-
thesis kit (Invitrogen). Quantitative real-time PCR 
(qRT-PCR) was performed using the EXPRESS SYBR 
GreenER qPCR SuperMix Kit (Invitrogen) accord-
ing to the manufacturer’s instructions. The following 
forward and reverse primer sequences were used to 
detect changes in gene expression: sp7, 5′-CCAGTGT 
CTACACCTCTC-3′ and 5′-ATGGAGTAGGAGTG 
TTGC-3′; runt-related transcription factor 2 
(RUNX2), 5′-CTCACTACCACACCTACCTG-3′ and 
5′-TCAATATGGTCGCCAAACAGATTC-3′; alkaline 
phosphatase (ALP), 5′-CTAACTCCTTAGTGCCAG 
AG-3′ and 5′-CATGATGACATTCTTAGCCAC-3′; FBJ 
murine osteosarcoma viral oncogene homolog (c-Fos), 
5′-CCTGTCAAGAGCATCAGCAG-3′ and 5′-GTCA 
GAGGAAGGCTCATTGC-5′; distal-less homeobox 
5 (DLX5), 5′-TGGCCCGAGTCTTCAGCTAC’ and 
5′-TGGTTGGTCGGTCTCTTTCT-3′; osteonectin 
(SPARC), 5′-TGTGGGAGCTAATCCTGTCC-3′ and 
5′-TCAGGACGTTCTTGAGCCAGT-3′; osteopon-
tin (OPN), 5′-GCTCTAGAATGAGAATTGCACTG-3′ 
and 5′-GTCAATGGAGTCCTGGCTGT-3′; collagen 
type 1a (COLA1a), 5′-CATGTTCAGCTTTGTGGACC 
TC-3′ and 5′-AGGTGATTGGTGGGATGTCTT-3′; 
insulin-like growth factor 1(IGF1), 5′-CTGTGATC 
TAAGGAGGCTG-3′ and 5′-TTCGTGTTCTTGTTGGT 
AGA-3′; and beta-actin (β-actin), 5′-CACCTTCTA 
CAATGAGCTGC-3′ and 3′-TCTTCTCGATGCTC 
GACGGA-3′. All RT-PCR primers were designed using 
Primer3 (Boston, MA) and purchased from Integrated 
DNA Technologies (Coralville, IA). The expression of 
human β-actin was used to normalize mRNA content. 
Samples were tested in triplicates. No-template controls 
and no-reverse transcription controls were included in 
each PCR run. Data was normalized to lnASCs exposed 
to CDS-ODM for 1 day to account for differences associ-
ated with serum.
Statistical analysis
All values are presented as mean ± standard error of the 
means (SEM). The statistical differences between two or 
more groups were determined by ANOVA, followed by 
post hoc Tukey multiple comparison tests. Statistical sig-
nificant was set at P < 0.05. Only statistically significant 
values were considered relevant. Analysis was performed 
using Prism (Graphpad Software, San Diego, CA).
Results
obASCs demonstrate reduced osteogenic differentiation 
potential in a growth factor depleted environment
To characterize the osteogenic potential of lnASCs and 
obASCs, these cells were induced with ODM for 21 days 
and calcium deposition was visualized with Aliza-
rin Red staining. No statistically significant difference 
was observed between lnASCs and obASCs cultured in 
ODM (Fig.  1a, b). However, when lnASCs and obASCs 
were cultured in CDS-ODM, visible differences in the 
amount of calcium deposition were apparent (Fig.  1c). 
lnASCs demonstrated a 1.6-fold and a 2.5-fold increase 
in osteogenic differentiation after 14 and 21 days, respec-
tively, while obASCs demonstrated a 1.1-fold and a 1.9-
fold increase in osteogenic differentiation after 14 and 
21  days, respectively (P  <  0.01; Fig.  1d). These findings 
suggest that obASCs have a diminished osteogenic capac-
ity in the absence of estrogens. To determine whether 
delivery of estradiol would restore the osteogenic differ-
entiation in obASCs, cells were induced with CDS-ODM 
supplemented with log fold increases of estradiol from 
100  pM to 10  μM. Both lnASCs and obASCs demon-
strated enhanced osteogenic differentiation in the pres-
ence of estradiol (Additional file 1: Fig. S1). Since delivery 
of estradiol restored the osteogenic differentiation capac-
ity of obASCs, these results indicate that estradiol, in 
part, is a necessary competent for osteogenic differentia-
tion of obASCs (Additional file 1: Fig. S1).
obASCs display reduced osteogenic differentiation 
capacity on PLGA scaffolds
To investigate the osteogenic differentiation potential of 
lnASCs and obASCs on a biodegradable scaffold, lnASCs 
and obASCs were seeded on a PLGA scaffold cultured in 
CDS-CCM and analyzed by Alizarin Red staining. After 
7  days, lnASCs seeded on scaffolds displayed enhanced 
osteogenesis to 1.5-fold, meanwhile obASCs seeded 
on scaffolds did not demonstrate similar osteogenic 
effects (P < 0.05, Fig. 2). Supplementation with estradiol 
restored the osteogenic capacity of obASCs cultured in 
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CDS-ODM, indicating that obASCs require estradiol for 
differentiation (Additional file 2: Fig. S2).
obASCs was unable to induce osteogenesis activity in vivo 
compared to lnASCs
To assess osteogenesis of lnASCs and obASCs on PLGA 
scaffolds in  vivo, critical size calvarial defects were cre-
ated in nude mice and left empty or treated with scaf-
folds, lnASC-seeded scaffolds, or obASC-seeded 
scaffolds. MicroCT was performed on the skulls 2 and 
16  weeks after implantation to visualize and quantify 
bone formation. At 2  weeks, no statistically significant 
difference was observed between any of the groups, 
which was expected given the lack of calcified bone at 
such an early time point (Additional file  3: Fig. S3). By 
16  weeks, mice treated with scaffolds generated more 
calcified regions (2.1-fold increase) compared to mice in 
the control group; however, these results were not sta-

































































Fig. 1 obASCs display reduced osteogenic differentiation in an estrogen depleted environment. a lnASCs (N = 6 donors) and obASCs (N = 6 
donors) were cultured in ODM and stained with alizarin red after 21 days for calcium deposition. b To quantify the amount of alizarin red staining, 
stains were eluted with CPC and optical density was read. c lnASCs (N = 6 donors) and obASCs (N = 6 donors) were cultured in CDS-ODM and 
stained with alizarin red after 14 and 21 days for calcium deposition. d To quantify the amount of alizarin red staining, stains were eluted with CPC 



































Fig. 2 obASCs seeded on scaffolds display reduced osteogenic 
differentiation compared to lnASCs. lnASCs and obASCs were 
seeded on PLGA scaffolds and induced with CDS-ODM for 7 days. a 
Scaffolds stained with Alizarin Red are shown. b Stains were eluted 
from scaffolds with CPC and quantified. Scale bar represents 1 mm. 
Bars, ± SEM. ***, P < 0.001
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scaffolds enhanced osteogenesis to 7.2-fold; meanwhile, 
the addition of obASCs only induced a 2.5-fold increase 
in calcified bone (P  <  0.05, Fig.  3). Histological analysis 
revealed significantly higher levels of collagen, visualized 
by Aniline Blue staining. Consistent with the microCT 
analysis, mice treated with scaffolds alone demonstrated 
higher levels of collagen, compared to mice without treat-
ment (P < 0.05; Fig. 4). Mice treated with lnASCs demon-
strated significantly higher levels of collagen deposition 
(3.2-fold), compared to mice treated with scaffold alone 
(1.3-fold) or obASC-seeded scaffolds (1.4-fold; P < 0.05; 
Fig. 4). Aniline blue demonstrated complete coverage of 
the defect, though this tissue had not completely ossified 
by microCT analysis. These results suggest that obASCs 
were unable to induce osteogenesis within scaffolds 
in vivo, indicating that obASCs may have reduced osteo-
genic properties compared to lnASCs. 
Calvarial defects treated with lnASCs or obASCs displayed 
reduced osteoclast activity
While ASCs have previously been shown to enhance 
osteogenesis through osteoblastogenesis, it is possible 
that ASCs may generate an environment that inhibits 
osteoclastogenesis to reduce the breakdown of bone. 
To assess whether lnASCs and obASCs within scaffolds 
altered osteoclast activity during early remodeling, skull 
sections were stained with TRAP and assessed quantita-
tively. At 2 weeks, defects implanted with scaffold alone 
demonstrated reduced osteoclast activity compared to 
those left untreated (Fig. 5). Defects treated with obASC 
within scaffolds demonstrated a reduction in osteoclast 
activity to 15.8  %; meanwhile, lnASCs within scaffolds 
demonstrated even less osteoclast activity with reduction 
to 8.7 % (Fig. 5). These results indicate that lnASCs pro-
vide an environment to support osteogenesis while inhib-
iting osteoclastogenesis.
obASCs display an altered osteogenic gene expression 
profile compared to lnASCs
To further investigate the reduced osteogenic differen-
tiation capacity of obASCs, lnASCs and obASCs were 
induced with CDS-ODM for 1, 7, 14, and 21  days, and 
the mRNA expression of osteogenic genes was assessed. 
lnASCs exposed to CDS-ODM for 1  day was chosen as 
the baseline control to compare across different time 
points and different cell types. lnASCs induced with CDS-
ODM demonstrated the most robust induction of osteo-
genic genes after 21  days  in Sp7 (434.0-fold), RUNX2 
(36.1-fold), ALP (720.5-fold), c-FOS (1534.1-fold), DLX5 
(753.8-fold), SPARC (436.5-fold), and OPN (627.6-fold), 
compared to lnASCs exposed to CDS-ODM for 1  day 
(Fig. 6). In contrast, obASCs induced with CDS-ODM did 
not demonstrate upregulation of most of these osteogenic 
genes; osteogenic genes RUNX2, ALP, cFOS, and SPARC 
were not upregulated in obASCs following induction dur-
ing any of the time points. Only Sp7 was upregulated in 
obASCs after 14 days (387.4-fold) and 21 days (743.9-fold) 
CDS-ODM, and a 444.9-fold increase in DLX5 expres-
sion was observed in obASCs after 14 days in CDS-ODM. 
Furthermore, lnASCs cultured in CDS-ODM demon-
strated a biphasic upregulation of COLA1a by 33.6-fold 
and 135.7-fold after 7 and 21  days, respectively (Fig.  6). 









































Fig. 3 obASCs seeded on scaffolds display reduced osteogenesis in vivo. Critical size calvarial defects were created in the right parietal bone of 
nude mice. Treatment groups included defects without scaffold or cells (empty), defects with scaffold only and defects treated scaffolds seeded 
with lnASCs or obASCs. a Representative 3D reconstructions of microCT scans performed at 16 weeks. b Quantification of microCT. Scale bar 
represents 1 mm. Bars, ± SEM. ***, P < 0.001, compared to untreated defects; ###, P < 0.001, compared between defects treated with scaffold and 
scaffolds seeded with lnASCs; ΦΦ, P < 0.01, compared between defects treated with scaffolds seeded with lnASCs and obASCs
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lnASCs induced with CDS-ODM displayed a bipha-
sic pattern of expression of IGF-1, with a 86.2-fold and 
113.5-fold induction in lnASCs after 7 days and 21 days in 
CDS-ODM (Fig. 6). In contrast, obASCs demonstrated a 
robust upregulation of COLA1a by 206.0-fold and IGF1 
by 145.0-fold after 7  days in CDS-ODM, without the 
biphasic induction after 21  days (Fig.  6). These findings 
together suggest that while lnASCs temporally upregulate 
osteogenic genes during early, mid, and late osteogenic 
differentiation, obASCs demonstrate diminished capacity 
to upregulate key osteogenic genes at specific time points 
during differentiation.
Discussion
Bone tissue engineering is an interdisciplinary field 
focused on the development of biological bone substi-
tutes that restore, maintain, or improve tissue function 
by applying the principles of engineering and life sciences 
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Fig. 4 Defects treated with lnASCs-seeded scaffolds demonstrate significant collagen deposition. Calvarial defects were created in the parietal 
bone of nude mice. Histology was conducted 16 weeks post operatively. a Representative images of sections stained with aniline blue are shown. b 
Quantification of collagen deposition. Bars, ± SEM. **, P < 0.01, compared to untreated defects; ##, P < 0.01, compared between defects treated with 
scaffold and scaffolds seeded with lnASCs. ΦΦ, P < 0.01, compared between defects treated with scaffolds seeded with lnASCs and obASCs
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Fig. 5 Calvarial defects treated with lnASC- or obASCs-seeded scaffolds display reduced osteoclastic activity. Calvarial defects were created in the 
parietal bone of nude mice. Histology was conducted 2 weeks post operatively. a Representative images of sections stained with TRAP, allowing 
osteoclasts to appear bright red. b Quantification of TRAP stain. Bars, ± SEM. ***, P < 0.001, compared to defects treated with neither scaffolds or 
cells; #, P < 0.05, compared between defects treated with scaffold and scaffolds seeded with lnASCs










































































































































































































Fig. 6 The gene expression pattern of lnASCs and obASCs differ during osteogenic differentiation. lnASCs (N = 6 donors) and obASCs (N = 6 
donors) were cultured in CDS-ODM and harvested after 1, 7, 14, and 21 days for qRT-PCR analysis of key osteogenic factors. Data is normalized to 
lnASCs cultured in CDS-ODM for 1 day, set to 1.0. Bars, ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 between lnASCs and obASCs
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[36]. The primary target of clinical therapeutic strategies 
is the regeneration of bone for structural reconstruction. 
Strategies aimed at stimulating bone healing to treat skel-
etal defects are pertinent due to the large number of bone 
grafting procedures performed annually worldwide [37, 
38].
Advances in utilizing sophisticated bone scaffolds 
eliminate the risk of disease transmission, reduce the 
number of surgical procedures performed, and reduce 
the risk of infection or immunogenicity [39]. These bone 
scaffolds provide an endless supply of synthetic and nat-
ural biomaterials, eliminating the need to center surgi-
cal procedures on available autologous bone. Lately, the 
addition of ASCs to the tissue engineering strategy has 
gained significant interest and attention. The synergis-
tic effects of biodegradable scaffolds and ASCs enhance 
bone formation by allowing ASCs to engraft and undergo 
osteogenic differentiation [40]. The restorable nature of 
these constructs also allows for the integration with the 
surrounding tissue and eventual replacement by new or 
existing host tissue [40]. Sándor demonstrated the syner-
gistic effect of ASCs, restorable scaffold, and growth fac-
tor in patients with craniofacial osseous defects, whereby 
delivery of tissue engineered constructs expedited bone 
regeneration at the site of implantation [41]. Additional 
large-scale studies are necessary to confirm the repro-
ducibility of this technique in a large cohort, but these 
preliminary findings are particularly promising. Fur-
thermore, it is unclear if the viability of the obASCs dif-
fers from the lnASCs and how long these cells persist 
in  vivo. Clinically, the improved bone formation in the 
lnASCs indicates that diabetic patients might benefit 
from lnASCs when faced with a non-healing bone defect. 
Alternatively, the obASCs might require implantation 
with additional osteogenic growth factors.
To ensure the successful regeneration of bone with 
ASCs as the cell source, studies investigating the ideal 
donor to harvest ASCs from are necessary. In the cur-
rent study, the impact of obesity on the bone regenera-
tive potential of lnASCs and obASCs was investigated. 
Consistent with previous reports [42, 43], the addition of 
lnASCs enhanced the osteoinductive effects of scaffolds 
both in vitro and in vivo, compared to the untreated con-
trol groups and groups treated with scaffold alone. Scaf-
folds seeded with obASCs demonstrated similar findings 
as scaffold alone, suggesting the addition of obASCs has 
no impact on bone regeneration. During the osteogenic 
differentiation of lnASCs, several transcription factors 
were notably upregulated, including RUNX2, ALP, cFOS, 
DLX5, SPARC, OPN, COLA1a, and IGF-1. RUNX2 is 
considered a central control gene within the osteoblast 
lineage, thereby enabling RUNX2 to directly stimulate 
downstream ALP, osteocalcin, OPN, COLA1a, bone 
sialoprotein, and RANKL [44, 45]. It is the coordinated 
upregulation of these osteogenic factors that leads to the 
differentiation of cells into osteoblasts and result in the 
deposit of extracellular matrix proteins that regenerates 
bone [44, 45].
In contrast to the robust osteogenic differentiation of 
lnASCs, obASCs in the present study displayed reduced 
osteogenic differentiation in adherent cultures, on scaf-
folds in culture, and on scaffolds in a critical size calvarial 
defect model. The reduced osteogenic differentiation cor-
related with reduced collagen deposition. These results 
would suggest that the osteoinductive effects of obASCs 
are attenuated compared to lnASCs. Studies have shown 
that obesity increases the presence of proinflammatory 
cytokines in circulation and in tissues, which may alter 
the osteogenic differentiation of ASCs and promote oste-
oclast activity and bone resorption [46–49]. Cao et  al. 
further demonstrated that high fat diet decreased cal-
cium availability for bone formation [48]. Together, these 
altered processes counteract the traditional thought that 
obesity due to mechanical load may be beneficial to bone 
[50].
The data demonstrate that the delivery of estradiol res-
cued the effects of obesity-related changes to osteogenic 
differentiation. This finding indicates that the high levels 
of estradiol associated with obesity may alter the biol-
ogy of ASCs such that estradiol is now essential for the 
maintenance of these cells. These results indicate that 
obesity may directly or indirectly alter ASC biology and 
lead to permanent imprinting on ASCs. With respect to 
tissue engineering, obesity appears to reduce the oste-
oinductive effects of ASCs and may reduce the efficacy of 
engineered constructs generated with obASCs as the cell 
source.
Mechanistically, the expression of key osteogenic genes 
was attenuated in obASCs during osteogenic differen-
tiation, compared to the expression pattern in lnASCs. 
obASCs displayed minimal RUNX2, ALP, cFOS, and 
SPARC expression. Interestingly, the levels of COLA1a, 
IGF-1, DLX5 and sp7 induction were temporally and 
spatially enhanced in obASCs, compared to lnASCs. 
It should be noted that while lnASCs display a biphasic 
upregulation of COLA1a and IGF-1, obASCs display a 
more robust response during early osteogenic differentia-
tion with no induction during late osteogenic differentia-
tion. As markers of late osteogenesis, the lack of COLA1a 
and IGF-1 in obASCs during late osteogenesis would 
suggest that obesity has altered osteogenic differentiation 
of these cells mechanistically. The robust upregulation 
COLA1a and IGF-1 during early osteogenic differentia-
tion is likely due to the activation of alternative osteo-
genic pathways. Previous studies have shown that IGF-1 
induces Dlx5, which in turn has been shown to induce 
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sp7 expression [51, 52]. Studies have shown that sp7 acts 
in the regulation of numerous osteoblast genes includ-
ing osteocalcin, SPARC, OPN, bone sialoprotein, and 
COLA1a [53]. Consistent with these previous reports, 
obesity may have a role in inhibiting downstream regu-
latory activity of sp7 and reducing the ability of sp7 to 
induce osteonectin and COLA1a expression. Together, 
these changes in the gene expression profile of obASCs 
during osteogenic differentiation, compared to lnASCs, 
are consistent with the poor osteogenic differentiation 
of these cells and highlight the underlying alterations to 
ASC osteogenic differentiation.
Conclusion
Collectively, the findings from this study would suggest that 
obASCs have diminished osteogenic differentiation capac-
ity and may be suboptimal as the cellular component to tis-
sue engineering approaches. Future studies are necessary to 
determine how obesity alters ASC biology. It is unknown 
whether it is the long-term direct contact with dysregulated 
adipose tissue or the exposure to the secretome of adipose 
tissue that alters ASCs. Additional studies are necessary to 
identify the pathways altered by obesity in ASCs in order to 
reverse the effects of obesity on ASC osteogenesis.
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